Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Information Update - Update: Pharmascience Inc. recalls 30 lots of 150 mg over-the-counter ranitidine in blister packs


OTTAWA, ON, March 11, 2022 /CNW/ - Pharmascience Inc. is recalling 30 lots of over-the-counter ranitidine drugs (150 mg tablets) packaged in blister packs, after tests found NDMA, a nitrosamine impurity, above the acceptable level in some lots. NDMA is classified as a probable human carcinogen, which means long-term exposure to levels above what is considered safe could increase the risk of cancer. The products are sold under various private labels. Please refer to the Affected Products table for detailed information on the recalled lots.

Health Canada maintains a list of ranitidine drugs affected by this issue. Please see the full advisory for more information, including what consumers should do.

Affected Products

Product  Name

DIN

Strength

Lot

ATOMA maximum strength acid reducer without
prescription (24 tablets)

02293471

 

150 mg

629744F

ATOMA maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632058H

Compliments maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632043B

Compliments maximum strength acid reducer without
prescription cool mint (24 tablets)

02293471

150 mg

629973A

CO-OP Care+ maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

629744C

Health One maximum strength acid reducer without
prescription (32 tablets)

02293471

150 mg

629744J

Health One maximum strength acid reducer without
prescription (32 tablets)

02293471

150 mg

632043H

Life Brand maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

629744H

Life Brand maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632058I

Life Brand maximum strength acid reducer without
prescription cool mint (48 tablets)

02293471

150 mg

629974B

Life Brand maximum strength acid reducer without
prescription cool mint (24 tablets)

02293471

150 mg

629974A

Option+ maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

629744G

Option+ maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632043D

Option+ maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632043E

Option+ maximum strength acid reducer without
prescription (8 tablets)

02293471

150 mg

632058A

Option+ maximum strength acid reducer without
prescription cool mint (24 tablets)

02293471

150 mg

629973B

Option+ maximum strength acid reducer without
prescription cool mint (24 tablets)

02293471

150 mg

631893C

PERSONNELLE maximum strength acid reducer
without prescription (24 tablets)

02293471

150 mg

629744E

PERSONNELLE maximum strength acid reducer
without prescription (24 tablets)

02293471

150 mg

632043A

PERSONNELLE maximum strength acid reducer
without prescription (24 tablets)

02293471

150 mg

632043F

PERSONNELLE maximum strength acid reducer
without prescription (24 tablets)

02293471

150 mg

632058J

PERSONNELLE maximum strength acid reducer
without prescription (8 tablets)

02293471

150 mg

629744B

PERSONNELLE maximum strength acid reducer
without prescription (8 tablets)

02293471

150 mg

632058B

PERSONNELLE maximum strength acid reducer
without prescription cool mint (24 tablets)

02293471

150 mg

629973C

PERSONNELLE maximum strength acid reducer
without prescription cool mint (48 tablets)

02293471

150 mg

629973D

PHARMASAVE maximum strength acid reducer without
prescription (8 tablets)

02293471

150 mg

629744A

Rexall maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

629744I

Rexall maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632043G

Rexall maximum strength acid reducer without
prescription (24 tablets)

02293471

150 mg

632058G

Rexall maximum strength acid reducer without
prescription (8 tablets)

02293471

150 mg

632058D

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
THE IAMStm BRAND LAUNCHES ONLINE KITTEN AND PUPPY HUBS TO EMPOWER PET PARENTS IN CANADA WITH EXPERT INFORMATION
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
TELUS Health enables health data interoperability in Nova Scotia
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a CAGR of 21%, says Coherent Market Insights
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Sectra publishes Annual Report and Sustainability Report for 2023/2024
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

More news about Health...


News published on and distributed by: